Wegovy, a widely popular weight-loss drug, has made a groundbreaking leap in heart disease care. In a significant development, Wegovy has been shown to reduce the risk of cardiac issues by 20% in heart disease patients who do not have diabetes.
This large, international study’s results have been highly anticipated, suggesting Wegovy’s benefits extend beyond weight loss to cardiovascular health.
Transforming Heart Disease Care
Dr. Michael Lincoff from the Cleveland Clinic highlighted the significance of this shift, stating that Wegovy has transitioned from being merely a weight-loss therapy to a treatment that reduces cardiovascular events.
This sentiment is echoed by Dr. Francisco Lopez-Jimenez of the Mayo Clinic, who views the findings as pivotal in altering heart treatment guidelines.
Study Insights and Implications
Published in the New England Journal of Medicine and presented at the American Heart Association’s annual meeting, the study included over 17,500 participants across 41 countries.
Participants, aged 45 and above with a BMI of 27 or higher, were tracked for an average of three years. They were assigned either weekly Wegovy injections or a placebo.
The study found a significant reduction in heart-related issues among Wegovy users compared to the placebo group.
Additionally, Wegovy users experienced an average weight loss of 9%, along with improvements in markers of heart disease like inflammation, cholesterol, and blood pressure.
Beyond Weight Loss
Dr. Martha Gulati from Cedars-Sinai Medical Center noted that these improvements began before significant weight loss, suggesting that Wegovy’s benefits extend beyond just shedding pounds.
However, it remains uncertain whether these results are a direct effect of the drug or a byproduct of weight loss.
Side Effects and Accessibility
Despite its benefits, around a third of the study’s participants reported serious side effects, leading to some discontinuing the treatment. Common issues included nausea, vomiting, and gastrointestinal problems.
Cost remains a concern, with Wegovy priced at approximately $1,300 per month and not typically covered by insurance or Medicare. However, the direct impact of obesity drugs on significant health issues might influence future coverage decisions.
Conclusion
Wegovy’s emergence as a potent tool in combating heart disease marks a significant advancement in medical treatment.
Its ability to reduce the risk of heart issues in patients without diabetes, coupled with its weight loss benefits, positions it as a potential cornerstone in heart disease management.
As research and understanding of Wegovy’s mechanisms continue to evolve, it could reshape the landscape of cardiovascular treatment and prevention.
The study can be found in New England Journal of Medicine.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and herbal supplements could harm your heart rhythm.
For more information about health, please see recent studies about how drinking milk affects risks of heart disease and cancer, and results showing DASH diet is good for your blood pressure, and vegetable diet may reduce heart disease risk.
Copyright © 2023 Knowridge Science Report. All rights reserved.
